Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 665 clinical trials
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, …

brachytherapy
androgens
adenocarcinoma
androgen suppression
adenocarcinoma of prostate
  • 0 views
  • 19 Feb, 2024
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

vulvar cancer
direct bilirubin
primary tumor
measurable disease
erythropoietin
  • 0 views
  • 19 Feb, 2024
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy.

neutrophil count
prostatectomy
carcinoma
  • 2 views
  • 19 Feb, 2024
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

oximetry
lymphoma
follicular lymphoma
remission
lymphoblastic lymphoma
  • 0 views
  • 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

interferon
recurrent neuroblastoma
measurable disease
antineoplastic
cns involvement
  • 0 views
  • 19 Feb, 2024
Irreversible Electroporation of Unresectable Liver Tumors

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

metastasis
cancer
irreversible electroporation
hepatoma
liver tumor
  • 0 views
  • 19 Feb, 2024
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow …

stereotactic body radiation therapy
monoclonal antibodies
stage ia2 lung cancer ajcc v8
non-small cell carcinoma
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

transitional cell carcinoma
adjuvant
alopecia
neuropathy
kidney function tests
  • 0 views
  • 19 Feb, 2024
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

adjuvant
platinum-based chemotherapy
measurable disease
cancer chemotherapy
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

castration-resistant prostate cancer
ATR
monoclonal antibodies
progestin
measurable disease
  • 0 views
  • 19 Feb, 2024